Replies to post #149703 on Biotech Values

[mcbio]

The MOS for the erlotinib control arm is assumed to be 7 months. So unless they have sicker patients in the trial the alternative has to be bearish if the interim is much earlier than expected.

So, is the interim much earlier than expected? Someone said the CEO recently gave a direct timeline about how long ago it was reached but I forgot the specific figure.